The prevalence and clinicopathological features of breast cancer patients with hepatitis B virus infection in China
Metrics: PDF 1048 views | HTML 1361 views | ?
He Wu1, Chunxia Zhao1, Vishnu Prasad Adhikari1, Linjie Lu2, Jianbo Huang1, Yuxian Wei1, Qingqing Luo1, Wei Dai1, Yutuan Wu1, Xin Li1, Kainan Wu1, Ling-Quan Kong1
1Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2Department of Thyroid and Breast Surgery, Liuzhou People’s Hospital, Liuzhou 545006, Guangxi, China
Ling-Quan Kong, email: firstname.lastname@example.org
Keywords: hepatitis B surface antigens, breast neoplasms, pathology, hepatitis B infection, epidemiology
Received: June 06, 2016 Accepted: December 12, 2016 Published: February 13, 2017
We performed a case-control study to investigate the prevalence and clinicopathological features of breast cancer patients with hepatitis B virus (HBV) infection in China. The clinical data for 2,796 female patients with newly diagnosed, primary breast cancer were evaluated. A total of 234 breast cancer patients with HBV infection (the case group; positive for hepatitis B surface antigen [HBsAg]) and 444 breast cancer patients without HBV infection (the control group; negative for HBsAg, hepatitis B surface antibody, hepatitis B envelope antigen, hepatitis B envelope antibody, and hepatitis B core antibody) were selected for study. Analysis of the clinicopathological features revealed that the metastatic axillary lymph node ratio was lower in the case group than the control group, as was the proportion of patients with pathological T stage ≥T2. No differences in the expression levels of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, p53, or Ki67 were observed between the case and control groups. These data indicate that the rate of HBV infection is high among female breast cancer patients in China, and that HBsAg-positive breast cancer patients were generally diagnosed at an earlier stage and had fewer lymph node metastases.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.